Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Credit Rating- Revision. CARE Ratings Limited has placed ratings of 'CARE BBB / CARE A3+' assigned to bank facilities of Gujarat Themis Biosyn Limited on 'Rating Watch with Negative Implications' following GTBL's major acquisition plans to be undertaken in the near-to-medium term.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited's promoter Sachin D. Patel has submitted a disclosure under SEBI Takeover Regulations for acquiring up to 5,25,000 equity shares from Pharmaceutical Business Group (India) Limited, worth up to Rs.20 Crores, at Rs. 382 per equity share.

Gujarat Themis Biosyn Limited

Pharmaceutical Business Group (India) Limited has submitted a disclosure under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding the creation of an indirect encumbrance on shares of Gujarat Themis Biosyn Limited (GTBL) held by PBGIL.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about General Updates on Arbitration matter, stating that the parties have amicably resolved the disputes and settled the matter mutually, with no material financial impact.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot for raising funds by issue of Equity Shares through Qualified Institutions Placement.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Postal Ballot and submitted the Exchange a copy of Srutinizers report along with voting results for raising funds by issue of Equity Shares through Qualified Institutions Placement.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot, related to raising funds by issue of Equity Shares through Qualified Institutions Placement.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Postal Ballot and submitted a copy of Srutinizers report along with voting results for the resolution of raising funds by issue of Equity Shares through Qualified Institutions Placement.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has received a disclosure under SEBI Takeover Regulations from Sachin D. Patel, a promoter of the company, regarding the acquisition of up to 5,25,000 equity shares from Pharmaceutical Business Group (India) Limited. The acquisition is an inter-se transfer among the promoter and promoter group.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited's promoter, Sachin D. Patel, has made a disclosure under SEBI Takeover Regulations for acquiring 24,97,190 equity shares from Themis Medicare Limited, citing exemption for inter se transfer among promoters and promoter group.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has submitted an investor presentation, highlighting its diversified pharma platform, expansion of fermentation capabilities, and forward integration strategy. The company has acquired Sanofi's Select and MicroBiopharm Japan, and has established a new R&D lab for developing new intermediate molecules and exploring additional applications for existing ones. The company has also doubled its annual fermentation capacity and ventured into API production as part of its forward integration strategy.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company, specifically an arbitration proceeding initiated against Optimus Drugs Private Limited for breach of supply agreement terms.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has closed its trading window from July 1, 2026, until 48 hours after the announcement of its unaudited financial results for the quarter ending June 30, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited clarifies the omission of Earnings Per Share (EPS) in their XBRL filing for the quarter ended 31-Mar-2026, stating it was an inadvertent technical error with no impact on financial performance or profitability.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has received a disclosure under SEBI Takeover Regulations from Sachin D. Patel, a promoter, regarding the acquisition of up to 26,00,000 equity shares from Themis Medicare Limited, worth up to Rs. 100 Cr, as part of an inter-se transfer among promoters and promoter group.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has been asked by the NSE to clarify its financial results for the quarter ended 31-Mar-2026, specifically regarding Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.